Effect of melatonin in selected populations of sleep-disturbed patients.

L I Brusco, I Fainstein, M Márquez, D P Cardinali
{"title":"Effect of melatonin in selected populations of sleep-disturbed patients.","authors":"L I Brusco,&nbsp;I Fainstein,&nbsp;M Márquez,&nbsp;D P Cardinali","doi":"10.1159/000014580","DOIUrl":null,"url":null,"abstract":"<p><p>In an open pilot study on the efficacy of melatonin in the treatment of sleep disorders, patients with sleep disturbances alone, patients with sleep disturbances and signs of depression and patients with sleep disorders and dementia received 3 mg melatonin p.o. for 21 days, at bed time. After 2-3 days of treatment, melatonin significantly augmented sleep quality and decreased the number of awakening episodes in patients with sleep disturbances associated or not with depression. Estimates of next-day alertness improved significantly only in patients with primary insomnia. Agitated behavior at night (sundowning) decreased significantly in dementia patients. In a second retrospective study, 14 Alzheimer's disease (AD) patients received 9 mg melatonin daily for 22-35 months. A significant improvement of sleep quality was found, while there were no significant differences between initial and final neuropsychological evaluation (Functional Assessment Tool for AD, Mini-Mental). The results indicate that melatonin can be useful to treat sleep disturbances in elderly insomniacs and AD patients.</p>","PeriodicalId":79565,"journal":{"name":"Biological signals and receptors","volume":"8 1-2","pages":"126-31"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000014580","citationCount":"81","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological signals and receptors","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000014580","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 81

Abstract

In an open pilot study on the efficacy of melatonin in the treatment of sleep disorders, patients with sleep disturbances alone, patients with sleep disturbances and signs of depression and patients with sleep disorders and dementia received 3 mg melatonin p.o. for 21 days, at bed time. After 2-3 days of treatment, melatonin significantly augmented sleep quality and decreased the number of awakening episodes in patients with sleep disturbances associated or not with depression. Estimates of next-day alertness improved significantly only in patients with primary insomnia. Agitated behavior at night (sundowning) decreased significantly in dementia patients. In a second retrospective study, 14 Alzheimer's disease (AD) patients received 9 mg melatonin daily for 22-35 months. A significant improvement of sleep quality was found, while there were no significant differences between initial and final neuropsychological evaluation (Functional Assessment Tool for AD, Mini-Mental). The results indicate that melatonin can be useful to treat sleep disturbances in elderly insomniacs and AD patients.

褪黑素对睡眠障碍患者的影响。
在一项关于褪黑激素治疗睡眠障碍疗效的开放试点研究中,仅有睡眠障碍的患者、有睡眠障碍和抑郁症状的患者以及有睡眠障碍和痴呆的患者每天服用3毫克褪黑激素,持续21天,在睡前服用。治疗2-3天后,褪黑素显著提高了睡眠质量,减少了与抑郁症相关或非抑郁症相关的睡眠障碍患者的觉醒次数。估计第二天的警觉性只有在原发性失眠患者中才有显著改善。痴呆患者夜间(日落)激动行为显著减少。在第二项回顾性研究中,14名阿尔茨海默病(AD)患者每天接受9毫克褪黑素治疗,持续22-35个月。发现睡眠质量有显著改善,而初始和最终神经心理学评估(AD功能评估工具,Mini-Mental)之间没有显著差异。结果表明,褪黑素可用于治疗老年失眠症和AD患者的睡眠障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信